Literature DB >> 2123559

Fluvoxamine in the treatment of menstrually related mood disorders.

A T Veeninga1, H G Westenberg, J T Weusten.   

Abstract

Twenty women with premenstrual complaints were treated in a double-blind placebo controlled trial during two consecutive menstrual cycles with fluvoxamine, a selective serotonin uptake blocker. A beneficial effect was found on somatic and affective symptoms in both treatment groups, the effect of fluvoxamine being not different from placebo. The results of this study do not support a role for serotonin in menstrually related affective symptoms.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2123559     DOI： 10.1007/bf02244113

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  2 in total

Review 1.  The relationship of menstrually related mood disorders to psychiatric disorders.

Authors:  P P Roy-Byrne; M C Hoban; D R Rubinow
Journal:  Clin Obstet Gynecol       Date:  1987-06       Impact factor: 2.190

2.  Premenstrual syndrome.

Authors:  J Bancroft; T Bäckström
Journal:  Clin Endocrinol (Oxf)       Date:  1985-03       Impact factor: 3.478
  2 in total
  6 in total

1.  Premenstrual dysphoric disorder: burden of illness and treatment update.

Authors:  Teri Pearlstein; Meir Steiner
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

2.  Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.

Authors:  Nirav R Shah; J B Jones; Jaclyn Aperi; Rachel Shemtov; Anita Karne; Jeff Borenstein
Journal:  Obstet Gynecol       Date:  2008-05       Impact factor: 7.661

Review 3.  Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Authors:  Uriel Halbreich; P M Shaughn O'Brien; Elias Eriksson; Torbjörn Bäckström; Kimberly A Yonkers; Ellen W Freeman
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Selective serotonin reuptake inhibitors for premenstrual syndrome.

Authors:  Jane Marjoribanks; Julie Brown; Patrick Michael Shaughn O'Brien; Katrina Wyatt
Journal:  Cochrane Database Syst Rev       Date:  2013-06-07

Review 5.  Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?

Authors:  Teri Pearlstein
Journal:  Drugs       Date:  2002       Impact factor: 9.546
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.